Pharma

Your Article Summary

See Latest Articles

AVI BioPharma Receives Key Patents for Drug Candidate AVI-6002 Targeting Ebola Zaire Virus Protein VP35
AVI BioPharma, 04/29/09

AVI BioPharma, Inc. , a developer of RNA-based drugs, today announced issuance of the second of two key U.S. patents covering the Company's candidate drug for the treatment of Ebola Zaire infection. The patents titled "Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection" , cover composition and methods to target the Ebola virus VP35 protein with a range of PMOplus compounds. The patents have an expiration date of Oct. 2025.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals